Physical Health United States Project #16301

Cycle for Survival

by Memorial Sloan-Kettering Cancer Center

Project Report | Dec 20, 2017
Cycle for Survival Update #15

By Cailie Burns | Development Officer

Earlier this year, an unprecedented medical milestone was reached. The results of the first 10,000 patients who had their tumors sequenced by MSK were revealed.

Based on the findings:

1,000 of these patients were matched with a clinical trial

37% of these patients had at least one actionable mutation in their tumor

Many patients’ sequencing results uncovered their cancer’s specific mutations, qualifying them for targeted treatments

Today, MSK researchers can look for cancer-causing alterations in 468 genes, and MSK is sequencing 600 to 800 patients monthly.

This is only the beginning, and with the help of donors like you, we can reach the next milestone.

This month, Cycle for Survival has launched the December Challenge – an initiative to raise $2 million by December 31 to purchase a DNA sequencer and fund genomic profiling. This technology is a game-changer, helping patients get the earliest and most precise treatment possible. Sequencing tumor DNA gives doctors the ability to not only develop more personalized treatments for patients, but also to increase the wealth of data and information to drive new and important investigations.

Here are some examples of the impact you are helping to fund:

Project GENIE, launched with the leadership of MSK’s Dr. Charles Sawyers, is an international data-sharing program, which enables institutions around the world to contribute sequencing data to a shared registry. By pooling insights, GENIE makes it easier for experts to study a large quantity of cancer-causing genetic mutations, which will ultimately inform treatment decisions. This unique collaboration is especially important for rare cancers.

Dr. David Solit, the director of the Kravis Center for Molecular Oncology at MSK, created the innovative Make-an-IMPACT initiative to provide patients with select rare cancers DNA sequencing at no cost. This brand new effort enhances MSK’s ability to discover the underlying genetic basis for rare cancers and helps match patients with clinical trials – regardless of which hospital they go to for treatment. This unprecedented initiative has been made possible largely by Cycle for Survival supporters.

The Cycle for Survival season begins next month! Bikes are over 90% full – sign up today and ride with us to beat rare cancers.

Join the Battle! Register to ride with us in 2018

Permalink

Sep 26, 2017
Cycle for Survival Update #14

By Cailie Burns | Manager of Leadership Giving and Corporate Sponsor

JOIN THE BATTLE

Thanks to donors like you, each and every dollar of the $34 million raised in 2017 is already at work funding innovative studies and clinical trials that are accelerating progress in the fight against rare cancers.

You are helping to empower scientists and doctors to make lifesaving discoveries and advance trailblazing innovations that will help patients everywhere. Raising $34 million this year—and more than $140 million in the eleven years since inception—is all thanks to the determined riders, supporters, patients, researchers, and physicians who are making a lasting impact, like you.

Here are just a few examples of what you are helping to fund:

Precision Prevention

When cancer is identified early, the likelihood of survival increases by 80 percent. Imagine finding someone’s disease long before it fully develops into cancer—and having the power to stop it immediately. Precision prevention is a new field set to change the future of cancer as we know it.

Most current screening methods are insufficient, and many miss the first signs of cancer entirely. Two exceptions are the Pap smear and colonoscopy: both find cancer at its earliest, most treatable stage. Cycle for Survival is seeding a groundbreaking endeavor, run by Luis Diaz, MD, which applies the concepts of precision medicine to healthy individuals in a bold step to ultimately increase survival rates. The team is creating tools to screen and flag those people most likely to develop cancer—triggering a life-saving medical intervention to reduce any chance of disease progression.

The Marie-Josée and Henry R. Kravis Center for Molecular Oncology

The CMO has ushered in a new era of cancer research, diagnosis, and treatment—leading to answers and hope for patients who otherwise had none. Cycle for Survival continues to support this transformative effort. The CMO fuels MSK’s expansive precision oncology venture, identifying cancer-driving genetic mutations and targeting them with superb accuracy.

In this era of personalized medicine, all roads lead back to the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO). Directed by Dr. David Solit, the CMO’s reach stretches far and runs deep. Thanks to Cycle for Survival, CMO researchers are constantly improving MSK-IMPACT, the all-important test used by physicians and scientists to explore and find the genetic mutations that cause cancer. The team recently hit a major milestone: announcing the results of their first 10,000 tumors sequenced. Undoubtedly this work is just getting started, and with Cycle for Survival’s backing, so much more will be achieved.

In just a few short months, participants will again take to the bikes and ride with friends, family, and colleagues to beat rare cancers. Registration for the 2018 events is open and bikes are filling fast! Sign up now and get your team started.

Links:

Attachments:

2017 Cycle for Survival Allocation (PDF)

2 Attachments

Permalink

Jun 30, 2017
Cycle for Survival Update #13

By Cailie Burns | Manager of Leadership Giving

‹ 1 2 3 4 5 6 7 8 ›

About Project Reports

Project reports on GlobalGiving are posted directly to globalgiving.org by Project Leaders as they are completed, generally every 3-4 months. To protect the integrity of these documents, GlobalGiving does not alter them; therefore you may find some language or formatting issues.

If you donate to this project or have donated to this project, you can receive an email when this project posts a report. You can also subscribe for reports without donating.